findmyKOL
Clinical trialNCT03461952TerminatedPhase 2Interventional

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

SponsorCanadian Cancer Trials GroupEnrollment4Advanced Solid Tumors
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Bcca - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

United States
  • Columbia University Medical Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Nivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Mar 2019
Primary completion
1 Jun 2021
Completion
9 Feb 2022
Last update posted
22 Feb 2024
Registered enrollment
4
Registry id
NCT03461952
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.